Retinal Vein Occlusion
Clarivate’s Epidemiology's coverage of retinal vein occlusion comprises epidemiological estimates of key patient populations. We report the prevalence of retinal vein occlusion for each…
Like other retinal disease therapy markets, the retinal vein occlusion (RVO) with macular edema (ME) market in the United States is unique in that it is dominated by Genentech’s Avastin, an…
Retinal vein occlusion (RVO) is a major cause of blindness, and affected approximately 1.6 million patients in 2018 in the United States. Patients are segmented by the anatomic location of the…
Retinal vein occlusion (RVO), estimated to affect 1.3 million U.S. adults aged 40 or older, is a retinal vascular disorder associated with macular edema (ME) and neovascularization and is the…